Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
IRVINE, Calif., Aug. 31, 2017 -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (Nasdaq:OCUL). Investors who purchased or otherwise acquired Ocular shares from May 5, 2017 through July 6, 2017, inclusive (the “Class Period”), are encouraged to contact the Firm by the September 5, 2017 lead plaintiff motion deadline.
If you purchased Ocular shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet, and until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, during the Class Period, Ocular made false and/or misleading statements and/or failed to disclose: that the Company’s management misled investors about DEXTENZA manufacturing issues, including that more than half of lots manufactured by the Company contain bad product; that such manufacturing issues could endanger the approval of DEXTENZA by the FDA; and that as a result, the Company’s public statements were materially false and misleading at all relevant times. On this news, Ocular’s stock price lowered materially, which caused investors harm according to the Complaint.
If you want to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for nearly two decades, by telephone at (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in certain jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
